Strand Therapeutics has raised a $153 million Series B round fresh off unveiling early, but promising results for a cancer therapy it's making with messenger RNA technology. The biotechnology startup ...
BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient ...
Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA therapies through clinical development. The Boston, US-based biotech recently ...
Imagine you're a scientist, tasked with the challenge of rapidly producing large quantities of high-quality messenger RNA (mRNA) for use in cutting-edge medical treatments. Where do you even start?
A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer ...
Marissa Russo is a former STAT intern supported by the AAAS Mass Media Science & Engineering Fellowship. An oral capsule can efficiently deliver liquid mRNA therapy directly to the gut, a possible new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results